Lapatinib, an epidermal growth factor receptor inhibitor, was used because of its ability to inhibit both ErbB2 (human epidermal growth factor receptor 2) and ErbB1 (epidermal growth factor receptor), which are frequently overexpressed in ependymomas. This evidence concerns the gene ERBB2 and ependymoma.